Reply: Elimination of Aspirin From PCI Pharmacotherapy

JACC Cardiovasc Interv. 2021 Jan 25;14(2):230-231. doi: 10.1016/j.jcin.2020.12.006.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Aspirin* / adverse effects
  • Coronary Vessels
  • Humans
  • Percutaneous Coronary Intervention* / adverse effects
  • Pilot Projects
  • Platelet Aggregation Inhibitors / adverse effects
  • Prasugrel Hydrochloride
  • Treatment Outcome

Substances

  • Platelet Aggregation Inhibitors
  • Prasugrel Hydrochloride
  • Aspirin